Glatiramer acetate

Neurologia

Volumn 17, Issue 5, 2002, Pages 244-258

  Comi, Giancarlo ^a   Moiola, L ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Disability; Experimental autoimmune encephalomyelitis; Glatiramer acetate; Magnetic resonance imaging; Multiple sclerosis; Relapsing remitting; Side effects; Th1 Th2 cells

Indexed keywords

ALANINE; AUTOANTIGEN; BETA INTERFERON; BETA1A INTERFERON; CARBAMAZEPINE; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; GLATIRAMER; GLUTAMIC ACID; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; META TYROSINE; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUTRALIZING ANTIBODY; PROTEOLIPID PROTEIN; SEROBIF; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; BRAIN ATROPHY; CLINICAL TRIAL; CLONAL ANERGY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DRUG ACTIVITY; DRUG CROSS REACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; HELPER CELL; HUMAN; HYPOTENSION; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; MUTAGENICITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE RISK; REMISSION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TREATMENT INDICATION;

ANIMALS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 0036558539     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8.
2. Arnon R. The development of Cop 1 (Copaxone®), an innovative drug for the treatment of multiple sclerosis: Personal reflections. Immunol Lett 1996;50:1-15.
3. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 1973;3:273-9.
4. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974;3:256-62.
5. Paterson PY. Autoimmune neurological disease: Experimental animal systems and implications for multiple sclerosis. In: Talal N, editor. Autoimmunity: Genetic, Immunologic, Virologic and Clinical Aspects. New York: Academic Press, 1977:643-92.
6. Arnon R, Teiltelbaum D. Desensitization of experimental allergic encephalomyelitis with synthetic peptides analogues. In: Davison AN, Cuzner ML, editors. The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis. New York: Academic Press, 1980:105-17.
7. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report. J Neurol Sci 1977 Apr; 31:433-8.
8. Bornstein MB, Miller AE, Teitelbaum D, Arnon R, Sela M. Treatment of multiple sclerosis with a synthetic polypeptide: Preliminary results. Trans Am Neurol Ass 1980;105:348-50.
9. Bornstein MB, Miller A, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: Trial of a synthetic polypeptide. Ann Neurol 1982;11:317-9.
10. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14.
11. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991;41:533-9.
12. Johnson KP. A review of the clinical efficacy profile of copolymer 1: New U.S. phase II trial data. J Neurology 1996;243(Suppl 1):S3-7.
13. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of the phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
14. Arnon R, Sela M, Teiltelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol 1996;243(Suppl 1):S8-S13.
15. Teitelbaum D, Arnon R, Sela M. Cop 1 as a candidate drug for multiple sclerosis: Personal reflections. J Neural Transm 1997;49(Suppl):85-91.
16. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979;123:2156-60.
17. Keith AB, Arnon R, Teteilbaum D, Caspary EA, Winsniewski. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 1979;42:267-74.
18. Ben-Nun A, Mendel I, Bakimer R, Frikis-Hareli M, Teitelbaum D, Arnon R, et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease. J Neurol 1996;243(Suppl 1):S14-S22.
19. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996;64:209-17.
20. Neuhaus O, Farina C, Wekerle H, Hohfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001;56:702-8.
21. Fridkis-Hareli M, Teitelbaum D, Gurevitch E, Pecht I, Brautbar C, Kwon OJ, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major hystocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 1994;91:4872-6.
22. Fridkis-Hareli M, Teitelbaum D, Arnon R. Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major hystocompatibility complex molecules on living antigen presenting cells. Cell Immunol 1995;163:229-36.
23. Webb C, Teitelbaum D, Arnon R, Sela M. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973;3:279-86.
24. Teitelbaum D, Aharoni R, Arnon R, Sela M. Specific inhibition of the T cell response to myelin basic protein by the synthetic copolymer Cop-1. Proc Natl Acad Sci USA 1988;85:9724-8.
25. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992;89:137-41.
26. Racke MK, Martin R, McFarland H, Fritz RB. Copolymer-1 induced inhibition of antigen-specific T cell activation: Interference with antigen presentation. J Neuroimmunol 1992;37:75-84.
27. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer 1. Proc Natl Acad Sci USA 1991;88:9528-32.
28. Lobel E, Riven-Krietman R, Amselem A, Pinchasi I. Copolymer-1. Drugs Future 1996 Feb;21(2):131-4.
29. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA 1999;96:634-9.
30. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000;55:1704-14.
31. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156-9.
32. Vergelli M, Hemmer B, Utz U, Vogt A, Kalbus M, Tranquill L, et al. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur J Immunol 1996;26:2624-34.
33. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105:967-76.
34. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-51.
35. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
36. Allen JE, Maizels RM. Th1-Th2: Reliable paradigm or dangerous dogma? Immunol Today 1997;18:387-92.
37. Swain SL. Helper T cell differentiation. Curr Opin Immunol 1999;11:180-5.
38. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
39. Kennedy JK, Torrance DS, Picka KS, Mahler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992;149:2496-505.
40. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 1997;94:10821-6.
41. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998;91:135-46.
42. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al. Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998;92:113-21.
43. Aharoni R, Teitelbaum D, Arnon R. T suppressor hybridoma and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol 1993;23:17-25.
44. Webb C, Teitelbaum D, Herz A, Arnon R, Sela M. Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 1976;13:333-7.
45. Lees MB, Kuchroo VK, Sobel RA. Myelin proteolipid protein: Its role in experimental allergic encephalomyelitis (EAE). Int Pediatr 1991;6:84-90.
46. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: Fine specificity and T cell receptor VB expression of encephalitogenic T cells. Eur J Immunol 1995;25:1951-9.
47. Van Noort JM, Van Sechel AC, Bajramovic JJ, Ouagmiri ME, Polman CH, Lassmann H, et al. The small heat-shock protein B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995;375:798-801.
48. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237-40.
49. Al-Sabbagh A, Miller A, Santos LMB, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL/J mouse. Eur J Immunol 1994;24:2104-9.
50. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75-85.
51. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci 2000;97:11472-7.
52. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Bergh FT, Dose T, et al. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000;97:7452-7.
53. Gran B, Tranquill LR, Chen M, Bilekova B, Zhou W, Dhib-Jalbut S, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000;55:1704-14.
54. Dabbert D, Rosner S, Kramer M, Scholl V, Tumani H, Mader M, et al. Glatiramer acetate (Copolymer-1)-specific, human T cell lines: Cytokine profile and suppression of T cell lines reactive against myelin basic protein (MBP): Neurosci Lett 2000;289:205-8.
55. Farina C, Bergh FT, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, et al. Treatment of multiple sclerosis with Copaxone (COP). Elispot assay detects COP-induced interleukin-4 and interferon-g response in blood cells. Brain 2001;124:705-19.
56. Sela M, Arnon R, Teitelbaum D. Suppressive activity of Cop-1 in EAE and its relevance to multiple sclerosis. Bull Inst Pasteur 1990;88:303-14.
57. Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci 1986;9:271-7.
58. Krogsgaard M, Wucherpfenning KW, Canella B, Hansen BE, Svejgaard A, Pyrdol J, et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med 2000;191:1395-412.
59. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000;97:7446-51.
60. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation? J Exp Med 1999;189:865-70.
61. Besser M, Vank R. Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th-2polarized expression of their receptors. J Immunol 1999;162:6303-6.
62. Baumhefner RW, Tourtellotte WW, Syndulko K, Shapshak P, Osborne M, Rubinstein G. Copolymer 1 as therapy for multiple sclerosis: The cons. Neurology 1988 Jul; 38(Suppl 2):69-72.
63. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1995;5:580-3.
64. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving Interferon beta-1b for multiple sclerosis: Report of a consensus conference. Neurology 1996;46:12-8.
65. Cohen JA, Grossman RI, Udupa JK, et al. Assessment of the efficacy of copolymer 1 in the treatment of Multiple Sclerosis by quantitative MRI. Neurology 1995;45(Suppl 4):A418.
66. Jonhson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-8.
67. IFNB Multiple sclerosis study group and the University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
68. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: A geographically based study. 3 Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
69. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak, et al. Sustained clinical benefits of glatiramer acetate in relapsing-remitting multiple sclerosis patients observed for 6 years. Multiple Sclerosis 2000;6(4):255-66.
70. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic Copolymer 1. Proc Natl Acad Sci USA 1991;88:9528-32.
71. De Seze J, Edan G, Labalette M, Dessaint JP, Vermersch P. Effect of glatiramer acetate (Copaxone) given orally in human patients: Interleukin-10 production during a phase 1 trial. Ann Neurol 2000;47:686.
72. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998;50:1127-33.
73. Comi G, Filippi M, Wolinsky JS and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multi-center, double-blind, randomized, placebo-controlled on the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7.
74. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
75. PRISMS Study group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
76. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herdnon RM, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
77. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-9.
78. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changed in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999:353:964-9.
79. Comi G, Filippi M, Wolinsky J. The extension phase of the European/Canadian MRI study demonstrates a sustained effect of glatiramer acetate in relapsing-remitting multiple sclerosis. J Neurol Sci 2001;187(Suppl 1):S434.
80. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M, and the European/Canadian Glatiramer acetate study group. Short-term brain volume changes in relapsing-remitting multiple sclerosis. Effect of glatiramer acetate and implications. Brain 2001;124:1803-12.
81. Van Waesberghe JH, Van Walderveen MAA, Castelijns JA, Scheltens P, Lycklama a Nijeholt GJ, Polman CH, et al. Pattern of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 1998;19:675-83.
82. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G and the European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into black holes. Neurology 2001;57:731-3.
83. Schwartz SM. A protective player in the vascular response to injury. Nature Medicine 7(News and Views) 2001;656-7.
84. Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 2000;247(3):220-1.
85. Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis 2001;68(4):287-8.
86. Korczyn AD, Nisipeanu P. Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel. J Neurol 1996;243(Suppl 1):S23-S26.
87. Johnson KP and the US. Phase III Copolymer 1 Study Group, Teitelbaum D, Arnon R and Sela M. Antibodies to copolymer 1 do not interfere with its clinical effect. Ann Neurol 1995;38:973[abstract].
88. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-60.
89. Milo R, Panitch H. Additive effects of copolymer 1 and interferon beta-1β on the immune response to myelin basic protein. J Neuroimmunol 1995;61:185-93.
90. Mizachi-Koll R, Karusiis D, Abramsky O. Synergistic in vivo effects of Cop-1 and interferon-β on hyperacute experimental autoimmune encephalomyelitis (EAE). Neurology 1997;48:A422.
91. Brod SA, Lindsey JW, Woolinsky. Combined therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFNα) does not improve experimental allergic encephalomyelitis. Ann Neurol 2000;47:127-31.